One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a compounded, off-brand version of its blockbuster weight-loss medications.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk and Eli Lilly battle it out over the latest blockbuster drugs.